>2018

Yuhan signs $1.25 billion licensing deal with Janssen

Lasertinib(GNS-1480), discovered by Genosco, was out-licensed to Janssen.

By | November 6th, 2018|

Early results from a 3rd gen EGFR-TKI in advanced NSCLC

Dr. Cho speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about a phase I/II trial of lazertinib(GNS-1480, YH25448), a highly selective and irreversible investigational 3rd-generation EGFR-TKI.

By | June 3rd, 2018|

ASCO 2018: Genosco/Yuhan Announce Results from Phase 1/2 Study of Lazertinib (YH25448, GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC

By | June 3rd, 2018|

YH25448, a 3rd Generation EGFR-TKI, in Patients with EGFR-TKI-resistant NSCLC: Phase I/II Study Results

Genosco's pipeline GNS-1480 (YH25448) was presented at ASCO 2018. *ASCO stands for American Society of Clinical Oncology Annual Meeting.

By | June 3rd, 2018|

YH25448, a 3rd generation EGFR-TKI, in patients with EGFR-TKI-resistant NSCLC: Phase I/II study results

ASCO 2018 Poster Board: #356 • Abstract 9033; Byoung Chul Cho - First Author, Severence Hospital

By | May 16th, 2018|

Genosco/Yuhan Announce Results from Phase 1/2 Study of YH25448(GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC to be Presented at ASCO 2018

Business Wire * May 16, 2018; Abstract - https://meetinglibrary.asco.org/record/161036/abstract

By | May 16th, 2018|

YH25448, an irreversible 3rd-generation EGFR TKI, exhibits superior anticancer effects with potent brain BBB penetration in NSCLC

Genosco's pipeline GNS-1480 (YH25448) was presented at AACR Annual meeting 2018. *AACR stands for American Association for Cancer Research.

By | April 18th, 2018|
Load More Posts